Aurobindo Pharma — full event log
Every event we have on file across every reporting year. The Data-by-year tab summarises the top 10 per year; this page shows them all.
← back to Data by year2024· 13 events
Aurobindo set 2025 goals including 12.5% carbon footprint reduction (SBTi well below 2°C), 20% renewable energy share (Power-to-Power), 35% water conservation/restoration, 60% co-processing of hazardous waste, 100% reuse/recycle of non-hazardous waste. Already achieved 16% carbon reduction (exceeded target), 14% renewables, 36% water restoration, 64% co-processing.
sustainability_report p.9
Operations certified to ISO 14001:2015 (environment), ISO 45001:2018 (occupational health & safety), SA 8000 (social accountability), ISO 9001:2015 (quality).
sustainability_report p.8
Aurobindo committed to Predicted No-Effect Concentrations (PNECs) targets for antibiotics in wastewater as per AMR Industry Alliance targets, addressing anti-microbial resistance risk.
sustainability_report p.7
Company stated it is in the process of initiating collection of Scope 3 emissions information from value chain partners. Scope 3 not yet quantified.
sustainability_report p.30
30MW solar PV plant at Pydibhimavaram generates ~43,000 MWh annually consumed in-house. Additional renewable supply sourced from associate power plants (NVNR Ramannapet I & II, 26% holdings). Together delivered 14% of power consumption against 20% 2025 goal.
sustainability_report p.27
Reduction in power consumption of 180.6 lakh kWh (~18 GWh) through installation of energy-efficient pumps, chillers under BOOT model, solar rooftop panels, VFDs, auto tube cleaning systems on chillers, replacement with energy-efficient compressors, synchronisation of nitrogen plants and optimum chiller/compressor loading.
sustainability_report p.30
More than 62% (15,269 tonnes in FY24) of hazardous waste diverted to cement industries for co-processing as alternative fuel, displacing fossil fuels. Achieved 64% co-processing of hazardous waste against 60% 2025 target. Avoids landfilling and incineration, supporting circular outcomes.
sustainability_report p.28
M/s Sharp & Tannan Associates provided reasonable assurance (higher bar than typical limited assurance) on identified sustainability information including energy, water, GHG, waste, safety, gender diversity per SEBI BRSR Core requirements.
sustainability_report p.1
Achieved Zero Liquid Discharge status at 5 units (erstwhile Aurobindo U-I, V, VIII, IX and Eugia-II). Treated wastewater reused for utility consumption.
sustainability_report p.26
Two new subsidiaries added in FY24: Auro Pharma LLC Russia (effective Jul 24, 2023) and Auro Trading Private Limited (Nov 22, 2023). Auroscience (Pty) Ltd liquidated Jun 4, 2023.
sustainability_report p.5
Aurobindo consumed 1,24,446 MWh renewable power in FY24, including ~43,000 MWh self-generated from its 30MW solar plant near Pydibhimavaram, Vizag, and purchased solar power from JV/associate companies (NVNR Ramannapet I & II Power Plants — 26% associates). Renewable share reached ~14% (power-to-power) against 2025 target of 20%. Strategy also includes shifting from coal to biomass/briquettes and piped natural gas at select units.
sustainability_report p.10
Company shifted from coal to biomass or briquette fuel at selected manufacturing units and adopted piped natural gas (PNG). Combined energy efficiency and fuel-switching initiatives reduced coal consumption by 4,736 MT in FY24 via improved steam condensate recovery and boiler efficiency.
sustainability_report p.30
Sustainable supply chain identified as a material risk. Mitigation includes shifting towards low-carbon logistics, supplier Code of Conduct (effective April 1, 2023) and engagements/audits. 51% of key starting material suppliers in India (for finished dosage drug products) assessed on Supplier Code of Conduct in FY24 vs 50% in FY23 — target 100%.
sustainability_report p.8